Arcturus Q3 net loss $35.3M; CSL partnership $200M upfront, up to $4.3B milestones

Arcturus Therapeutics Holdings Inc.

2022-Q3 EPS reported -$4.09 revenue$45,706,000

Revenue $13.4M (Q3 2022) vs $2.4M YoY; net loss $35.3M ($1.33 per share).
Cash $237.7M at Sep 30, 2022, down from $370.5M at Dec 31, 2021.
CSL Seqirus collaboration: $200M upfront, up to $4.3B milestones, 40% profit share on COVID vaccines.
BARDA award of up to $63.2M for self-amplifying mRNA pandemic influenza vaccine development.
ARCT-810 OTC deficiency Phase 2 dosing starts Q4 2022; ARCT-032 CTA filing expected by year end.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Arcturus Therapeutics Holdings Inc. reported third quarter ended September 30, 2022 results: revenue $13.4 million, net income net loss of approximately $35.3 million, or ($1.33) per basic and diluted share.

Period: third quarter ended September 30, 2022
Revenue: $13.4 million
Net income: net loss of approximately $35.3 million, or ($1.33) per basic and diluted share
Result: reported results

Exact text from the filing

from research and development arrangements with pharmaceutical and biotechnology partners. For the three months ended September 30, 2022, the Company reported revenue of $13.4 million compared with $2.4 million for the three months ended September 30, 2021, and $27.1 million for the three months ended June 30, 2022. Revenue increased by $10.9 million during

View on SEC.gov

Browse all earnings releases →

Arcturus Therapeutics Holdings Inc. filing history →

Source: SEC EDGAR

accession 0001193805-22-001504

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.